Prostatic Neoplasms, Castration-Resistant
4 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Neoplasms, Prostatic Neoplasms
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Androgen receptor signaling inhibitor (ARSI) + VIR-5500 for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Omeprazole 80 mg twice daily for prostatic neoplasms, castration-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VIR-5500 for prostatic neoplasms, castration-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.